NSAID Tolerance Can Be Restored in NECD Even in the Absence of Complete Remission of Urticaria
Authors:
- Merve Hormet IgdeMIMerve Hormet Igde
- Pelin KorkmazPKPelin Korkmaz
- Semra DemirSDSemra Demir
- Osman Ozan YegitOYOsman Ozan Yegit
- Derya ÜnalDÜDerya Ünal
- Merve Dilşad AtaseverMAMerve Dilşad Atasever
- Leyla BölekLBLeyla Bölek
- Selin Ece GüzelSGSelin Ece Güzel
- Nevzat KahveciNKNevzat Kahveci
- Mehmet Emin SezginMSMehmet Emin Sezgin
- Şule Çelik KamacıŞKŞule Çelik Kamacı
Open Access
- 21 October 2026
- journal article
- research article
- Published by Wiley in Clinical and Translational Allergy
- Vol. 16 (10) , e70216
Abstract
Background/Aim: Data on the course of nonsteroidal anti‐inflammatory drug (NSAID) hypersensitivity in NSAID‐exacerbated cutaneous disease (NECD) are limited. We aimed to evaluate NSAID tolerance in NECD patients with well‐controlled urticaria. Methods: 142 patients with well‐controlled urticaria [Urticaria Control Test (UCT) ≥ 12; Urticaria Activity Score over 7 days (UAS7) ≤ 6] underwent a single blind, placebo‐controlled acetylsalicylic acid (ASA) provocation test. Patients were categorized into three groups based on their treatment; omalizumab, antihistamine, or no treatment. Results: The median age of the patients was 40 years (IQR 31.5–52), and 79.6% were female. The median disease duration of chronic spontaneous urticaria (CSU) was 4 years (IQR 2–8). The ASA provocation test was positive in 29 patients (20.4%). Positive patients had lower UCT and higher UAS7 scores (both p < 0.001). ASA provocation test positivity was more common in the antihistamine group compared to both the omalizumab ( p = 0.001) and untreated groups ( p < 0.001). ROC analysis showed that UCT ≤ 15 predicted ASA provocation test positivity with 72.4% sensitivity and 83.2% specificity, while UAS7 ≥ 4 predicted positivity with 72.4% sensitivity and 86.7% specificity. The negative predictive values (NPV) were 92.2% and 92.5%, respectively. Conclusion: To our knowledge, this is the first study to demonstrate, in a large NECD cohort, that NSAID tolerance can be achieved in patients with well‐controlled urticaria under different treatment modalities, regardless of complete remission status. UCT ≤ 15 and UAS7 ≥ 4 are useful clinical predictors of provocation test positivity and, given their high NPVs, are particularly valuable for excluding positivity.Keywords
This publication has 16 references indexed in Scilit:
- Chronic spontaneous urticaria remission definition and therapy stepping down: World Allergy Organization position paperJournal of Allergy and Clinical Immunology, 2024
- Prospective analysis of clinical evolution in chronic urticaria: Persistence, remission, recurrence, and pruritus aloneWorld Allergy Organization Journal, 2022
- Drug allergy: A 2022 practice parameter updateJournal of Allergy and Clinical Immunology, 2022
- Omalizumab-Induced Aspirin Tolerance in Nonsteroidal Anti-Inflammatory Drug–Exacerbated Respiratory Disease Patients Is Independent of Atopic SensitizationThe Journal of Allergy and Clinical Immunology: In Practice, 2022
- Clinical Control of CSU with Antihistamines Allows for Tolerance of NSAID-Exacerbated Cutaneous DiseaseThe Journal of Allergy and Clinical Immunology: In Practice, 2020
- IgE allergy diagnostics and other relevant tests in allergy, a World Allergy Organization position paperWorld Allergy Organization Journal, 2020
- Development and validation of the Urticaria Control Test: A patient-reported outcome instrument for assessing urticaria controlJournal of Allergy and Clinical Immunology, 2014
- Genetics of Hypersensitivity to Aspirin and Nonsteroidal Anti-inflammatory DrugsImmunology and Allergy Clinics of North America, 2013
- Omalizumab for the Treatment of Chronic Idiopathic or Spontaneous UrticariaNew England Journal of Medicine, 2013
- Clinical Management of Nonsteroidal Anti-inflammatory Drug HypersensitivityWorld Allergy Organization Journal, 2008